Results 61 to 70 of about 10,090 (144)

Navigating the Data Gaps of Ageing Among Women Living With HIV

Journal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Caroline A. Sabin, Nomathemba Chandiwana, Anchalee Avihingsanon, Nicoletta Policek   +3 more
wiley   +1 more source

Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysisResearch in context

EClinicalMedicine
Summary: Background: Dolutegravir and bictegravir are frequently prescribed second-generation integrase strand transfer inhibitors. Although sex and gender influence drug pharmacokinetics, little is known about the differences in side effects ...
Zhou Fang, Tetiana Povshedna, Rowan Patterson, Erin Ready, Helene C.F. Cote, Melanie C.M. Murray, Elizabeth M. King   +6 more
doaj   +1 more source

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

Drug Design, Development and Therapy, 2015
Christopher E Kandel,1 Sharon L Walmsley1,21Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Division of Infectious Diseases, University Health Network, Toronto, ON, CanadaAbstract: Dolutegravir is the newest integrase strand transfer
Kandel CE, Walmsley SL
doaj  

Dyslipidemia and Its Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross-Sectional Study

AIDS Research and Treatment
Conclusion: The prevalence of dyslipidemia among people living with HIV on a dolutegravir-based ART was high, occurring in nearly three-quarters of the participants.
Mohammed Jemal, Adane Adugna, Mamaru Getinet, Baye Ashenef, Gelagey Baye, Desalegn Abebaw, Zigale Hibstu Teffera, Wastina Bitewlign, Anemut Tilahun, Nuredin Chura Waritu, Tabarak Malik, Enyew Fenta Mengistu   +11 more
doaj   +1 more source

Effectiveness of dolutegravir-based treatment among HIV/AIDS patients in Nkembo Outpatient Treatment Center, Gabon

AIDS Research and Therapy
Background HIV/AIDS therapy continues to make an enormous contribution to improving the well-being of HIV/AIDS patients globally. In Gabon, dolutegravir is administered to HIV/AIDS patients from first-line treatment.
Christian Mangala, Rolf Moukanda-Ifoundou, Denis Maulot-Bangola, Alain Moutsinga, Christian Mombo-Maganga, Serge Christian Okolongo-Mayani, Brice Ongali, Guy Joseph Lemamy, Rachyda Massolou-Outata   +8 more
doaj   +1 more source

Potential benefit of dolutegravir once daily: efficacy and safety

HIV/AIDS: Research and Palliative Care, 2013
Alessandra Fantauzzi,1 Ombretta Turriziani,2 Ivano Mezzaroma11Department of Clinical Medicine, 2Department of Molecular Medicine, Sapienza, University of Rome, Rome, ItalyAbstract: The viral integrase enzyme has recently emerged as a primary alternative ...
Fantauzzi A, Turriziani O, Mezzaroma I
doaj  

Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania

AIDS Research and Therapy
Background The World Health Organization recommends dolutegravir-based antiretroviral therapy (ART) as the preferred first-line regimen for HIV treatment.
Revocatus T. Majula, Clement N. Mweya
doaj   +1 more source

¿La combinación dolutegravir y rifampicina en los pacientes no incluidos en los ensayos clínicos es también eficaz y segura en el binomio VIH-infección micobacteriana? Casos de la práctica clínica

Medicina Clínica Práctica
Resumen: Introducción: las infecciones micobacterianas (IM) y la infección por VIH (iVIH) siguen siendo un binomio frecuente. La rifampicina dificulta el uso de los antirretrovirales.
Sara Fontserè Recuenco, Rafael Luque-Márquez   +1 more
doaj   +1 more source

A review of dolutegravir-associated weight gain and secondary metabolic comorbidities

SAGE Open Medicine
Dolutegravir is an integrase inhibitor and is recommended by the World Health Organization as the preferred first-line and second-line human immunodeficiency virus treatment in all populations.
Mohammed Jemal
doaj   +1 more source

Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women

CPT: Pharmacometrics & Systems Pharmacology
Optimal dosing in pregnant and lactating women requires an understanding of the pharmacokinetics in the mother, fetus, and breastfed infant. Physiologically‐based pharmacokinetic (PBPK) modeling can be used to simulate untested scenarios and hence ...
Jia Ning, Amita Pansari, Karen Rowland Yeo, Aki T. Heikkinen, Catriona Waitt, Lisa M. Almond   +5 more
doaj   +1 more source